SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) April 29, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On April 29, 1998 Biocontrol Technology, Inc.
(NASDAQ:BICO) announced today that progress continues toward
obtaining a CE Mark for the Diasensor 1000 noninvasive glucose sensor.
Its Notified Body, TUV Rheinland Product Safety GmbH, Germany, has
reviewed Biocontrol's recently submitted Technical File and requested
some clarification and information on certain points. Such
reciprocation is an expected part of CE Mark Technical File
reviews, and Biocontrol expects to fulfill the requests next
week. When supplied, the requested information should further
clarify the Technical File and assist TUV in their review of the
Diasensor 1000 for CE Marking.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: April 29, 1998
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
For More Information, Call:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL UPDATES CE MARK APPLICATION PROGRESS
Pittsburgh, PA - April 29, 1998 - Biocontrol Technology,
Inc. (Nasdaq:BICO) announced today that progress continues toward
obtaining a CE Mark for the Diasensor 1000 noninvasive glucose
sensor. Its Notified Body, TUV Rheinland Product Safety GmbH,
Germany, has reviewed Biocontrol's recently submitted Technical
File and requested some clarification and information on certain
points. Such reciprocation is an expected part of CE Mark
Technical File reviews, and Biocontrol expects to fulfill the
requests next week.
When supplied, the requested information should further
clarify the Technical File and assist TUV in their review of the
Diasensor 1000 for CE Marking.
TUV will then respond to Biocontrol's CE Mark application as
soon as the review is completed.
When achieved, the CE Mark on the Diasensor will signify
that the product meets the mandatory health and safety
requirements to be marketed in the 15-member European Union (EU)
with a diabetic population of approximately 15 million. The
first two steps in obtaining the CE Mark were completed by the
Company in October 1997 and January 1998 resulting in ISO 9001
registration for its Indiana, PA manufacturing and product
development facilities.
Biocontrol Technology, Inc. (www.bico.com) has its corporate
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
